Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05220293




Registration number
NCT05220293
Ethics application status
Date submitted
21/01/2022
Date registered
2/02/2022

Titles & IDs
Public title
Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream
Scientific title
The Effect of Betamethasone Dipropionate on Patients With Eosinophilic Chronic Rhinosinusitis
Secondary ID [1] 0 0
OT-007
Universal Trial Number (UTN)
Trial acronym
OT-007
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Rhinosinusitis (Diagnosis) 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Betamethasone Dipropionate Nasal Cream 0.0644%
Treatment: Devices - Pre-filled syringe and applicator device

Experimental: Betamethasone Dipropionate Nasal Cream 0.0644% Treatment - Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).


Treatment: Drugs: Betamethasone Dipropionate Nasal Cream 0.0644%
Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.

Treatment: Devices: Pre-filled syringe and applicator device
Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in 4 cardinal symptoms score (4CSS) from Baseline to Week 3.
Timepoint [1] 0 0
Baseline to Week 3
Primary outcome [2] 0 0
Change in Visual Analogue Scale (VAS) (0-10) evaluating global disease severity score from Baseline to Week 3.
Timepoint [2] 0 0
Baseline to Week 3
Primary outcome [3] 0 0
Change in SNOT-22 Score from Baseline to Week 3.
Timepoint [3] 0 0
Baseline to Week 3
Primary outcome [4] 0 0
Change in Modified Lund Mackay Postoperative Endoscopy Score from Baseline to Week 3.
Timepoint [4] 0 0
Baseline to Week 3
Primary outcome [5] 0 0
Overall Patient Global Impression of Change at Week 3.
Timepoint [5] 0 0
Week 3
Secondary outcome [1] 0 0
BMDP Cream retention time on the sinus
Timepoint [1] 0 0
Treatment visit to Week 3
Secondary outcome [2] 0 0
To assess the safety of one application of BMDP CREAM onto the sinus
Timepoint [2] 0 0
Treatment visit to Week 3

Eligibility
Key inclusion criteria
* Adult patients with a clinically confirmed diagnosis of eCRS by a ENT undergoing maximal medical therapy as part of their standard of care.
* Having undergone functional endoscopic sinus surgery at least 6 months prior to enrolment.
* Participants with an endoscopic bilateral nasal polyp score of =5 out of a maximum score of 8
* Score > 2 on disease severity visual analogue scale (VAS)
* A minimum body weight >=40 kilograms (kg) at screening visit
* Gender: Male or female (females of childbearing potential must use adequate birth control methods and not plan to get pregnant during the course of the study).
* Informed consent: Willingness to give written informed consent and willingness to participate to and comply with the study.
* Age =18 but <80 years.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subjects with known hypersensitivity or contraindications to Betamethasone Dipropionate, corticosteroids or topical anaesthesia.
* Subjects with sino-nasal abnormalities, disease or implanted devices that prevent application of the therapy.
* Previous enrolment in this study.
* Subjects currently required systemic corticosteroid use or receiving biologic therapy as part of their disease management plan or who meet the PBS criteria for severe lower airway disease.
* Subjects with history or current glaucoma or cataract or if they have abnormal IOP at screening or pre-treatment (abnormal IOP is defined as greater than 21 mm Hg).
* Subjects with other conditions that could lead to elevated eosinophils such as Hypereosinophilic Syndromes, including Churg-Strauss Syndrome, or Eosinophilic Esophagitis.
* Subjects with acute sinusitis.
* Subjects with known immunodeficiency.
* Subjects with Diabetes (Type 1).
* Subjects with cystic fibrosis.
* Pregnant subjects or subjects currently lactating as the effect on human pregnancy is unknown.

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/02/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/12/2023
Sample size
Target
Accrual to date
Final
2
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Oticara Clinical Trial Site - Sydney
Recruitment postcode(s) [1] 0 0
2000 - Sydney

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Oticara Australia PTY LTD
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Oticara Clinical
Address 0 0
Oticara Australia PTY LTD
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
There is not a plan to make IPD available.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05220293